In a previous network meta-analysis assessing approved drugs for the treatment of overweight and obesity, it was observed that GLP-1 analogs (semaglutide and liraglutide) might induce adverse effects resulting in treatment discontinuation [35]. The gene discussed is GLP1R; the disease is obesity disorder.